BIO Notebook, Day 3: Lilly Expands R&D Site, Sigilon Raises Cash And CytomX Talks Deal Strategy

Day three at the BIO International Convention included an off-site visit to Lilly's newly expanded R&D site as well as conversations with Sigilon about the $23m Series A venture funding round it announced that morning and with CytomX about its dealmaking strategy.

David Ricks
Lilly CEO David Ricks • Source: Eli Lilly & Co.

Eli Lilly & Co. coaxed a few BIO International Convention attendees, including Scrip, away from the San Diego Convention Center on June 21 to watch President and CEO David Ricks and others cut the ribbon on a newly expanded research and development site nearby that's responsible for the newly approved psoriasis therapy Taltz (ixekizumab) and two other products that are inching toward the market.

Day three also brought interviews with Sigilon Therapeutics Inc., which revealed that morning that it closed a $23m Series A...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Strategy

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.